The new scientifically validated Ayurvedic drug to fight Type 2 Diabetes has been launched by CSIR (Council of Scientific and Industrial Research) lab in Lucknow, India. Named as ‘BGR-34’, the pill was developed by the two government funded CSIR laboratories — Central Institute for Medicinal and Aromatic Plant (CIMAP) and National Botanical Research Institute (NBRI). In addition, the herbal drug is manufactured and marketed by Aimil Pharmaceuticals in New Delhi.
No clinical trials were conducted to validate the drug for any side effects. A CSIR official said that the drug do not pose any side effect although the drug was not tested on humans. However, the claim made many skeptical.
While explaining ingredients of the drug, Dr AKS Rawat, senior principal scientist, NBRI said that the drug contains extracts from four plants mentioned in Ayurveda and it does not boast any side effects. The scientifically validated drug was tested on animals and researchers found that in 67 percent cases the drug was effective. The CSIR scientists are too confident that there isn’t any need of clinical trial to validate the anti-diabetes medicine for its side effects.
While explaining the working of drug, NBRI scientists said that the drug has several functionalities — it boosts immune system, reduce chances of complications due to persistent high blood glucose levels, impart a good quality life to patients with high blood sugar levels and check for free radicals, also it acts as antioxidants.
What’s surprising about the drug is not that it hasn’t been validated in clinical trials but its high price. One tablet of BGR-34 costs Rs 5 which way costlier than most of the allopathic medicines. A pack of 100 tablets of BGR-34 costs Rs 500. While on the contrary, an allopathic diabetes drug named Melmet costs Rs 25 for pack of 15 tablets. The prices are shockingly high since most of the herbal and ayurvedic medicines in India are funded by the government.